Sarmad Sadeghi, MD, PhD

Dr. Sadeghi joined the faculty in the Division of Oncology at the University of Southern California in 2013. A clinician-scientist with NIH R01 funding, his clinical and research focus centers on genitourinary malignancies, with particular expertise in bladder, kidney, and prostate cancers.
He serves as principal investigator of the NIH R01 grant R01CA293348 and as study chair and principal investigator for multiple multicenter clinical trials, including SWOG S1937. A member of SWOG, he also holds the role of Genitourinary Group Chair for the California Cancer Consortium.
Dr. Sadeghi is widely published, with numerous original articles and abstracts appearing in peer-reviewed journals and presented at international meetings.
He earned his medical degree (MD) from Tehran University of Medical Sciences. He later completed a Master of Science (MS) in Health Informatics and a Doctor of Philosophy (PhD) in Public Health Management and Policy Sciences at the University of Texas Health Science Center at Houston. His postgraduate training included an internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation, followed by a hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute.

• Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
  NIH · R01CA293348 · Jun 1, 2025 – Apr 30, 2030 · Role: Principal Investigator
• A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma i ? ? Where can I find more information about this trial? Key information This trial is for adults 18 years or older being Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
  NIH/NCI · SWOG S1937 · Feb 16, 2021 – Mar 13, 2026 · Role: Study Chair and Principal Investigator
• A randomized double blind phase II trial of axitinib +/- OX40 Ab in mRCC patients previously treated with VEGF and PD1/PDL1 Ab
  Pfizer · Jan 1, 2016 – Dec 31, 2026 · Role: Principal Investigator
• Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder
  NIH/NCI/CTEP · NCI-9653/PHII-130 · Jun 1, 2015 – Mar 1, 2017 · Role: Study Chair and Principal Investigator
• A phase II trial of sEphB4-HSA in combination with Anti PD1 Antibody Pembrolizumab (MK-3475) in solid tumors
  Merck · Jan 1, 2015 – Dec 31, 2025 · Role: Principal Investigator

• Comparative Effectiveness and Cost-Effectiveness of an Artificial Intelligence Workflow for Small Renal Mass Diagnosis on Computed Tomography. Urol Pract. 2026 Jun 03; 101097.. View in PubMed
• Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncol Pract. 2025 Nov 18.. View in PubMed
• End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2025 11 10; 43(32):3536-3544.. View in PubMed
• Editorial Comment. J Urol. 2025 Sep; 214(3):306-307.. View in PubMed
• The outcomes of salvage robotic radical prostatectomy following radiation versus focal therapy: Does the primary treatment modality matter? BJUI Compass. 2025 May; 6(5):e70019. Ghoreifi A, Ramacciotti . View in PubMed
• EphB4-ephrin-B2 are targets in castration resistant prostate cancer. Br J Cancer. 2025 May; 132(8):679-689.. View in PubMed
• USPSTF Recommendations and Colorectal Cancer in Younger Adults-Current Challenges and Future Opportunities. JAMA Netw Open. 2024 10 01; 7(10):e2436305.. View in PubMed
• EphrinB2: Expression of a novel potential target in renal cell carcinoma. Indian J Urol. 2023 Jul-Sep; 39(3):223-227.. View in PubMed
• The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 03; 14(23).. View in PubMed
• EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 01 20; 41(3):640-650.. View in PubMed
• Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol. 2020 11; 7(1).. View in PubMed
• Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis. Am J Clin Oncol. 2020 06; 43(6):428-434.. View in PubMed
• How to optimize cancer therapy when coronavirus hits the fan. Am J Manag Care. 2020 06; 26(5 Spec No.):SP167.. View in PubMed
• EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathol Res Pract. 2020 Jun; 216(6):152967.. View in PubMed
• Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clin Genitourin Cancer. 2020 10; 18(5):351-360.e3.. View in PubMed
• Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? Eur Urol Focus. 2020 07 15; 6(4):623-626. Basu A, Sadeghi S . View in PubMed
• Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863.. View in PubMed
• Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 10 10; 37(29):2682-2688.. View in PubMed
• Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1.. View in PubMed
• Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol. 2019 01; 37(1):1-11.. View in PubMed
• Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551.. View in PubMed
• Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477.. View in PubMed
• Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 07; 35(7):459.e15-459.e24.. View in PubMed
• Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527.. View in PubMed
• Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4).. View in PubMed
• Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9.. View in PubMed
• Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48.. View in PubMed
• Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin Oncol. 2012 Oct; 39(5):608-14.. View in PubMed
• Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer. 2012 Jul 01; 118(13):3277-82.. View in PubMed
• Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472.. View in PubMed
• A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11.. View in PubMed
• Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8.. View in PubMed
• Mitral valve recurrence of a left atrial myxoma. Eur J Cardiothorac Surg. 2002 Mar; 21(3):568-73.. View in PubMed
• Determinants of operative mortality following primary coronary artery bypass surgery. Eur J Cardiothorac Surg. 2002 Feb; 21(2):187-92.. View in PubMed
• Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51.. View in PubMed

• Daneshmand, Siamak
• Lenz, Heinz-Josef
• Gill, Inderbir
• Djaladat, Hooman